BioPharma Dive - Latest News

Bluebird, at risk of default, agrees to take-private deal

The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of what it was once worth years ago.

Feb 21, 2025 - 16:30
 0
Bluebird, at risk of default, agrees to take-private deal

The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of what it was once worth years ago.

Read More

Tags:

Previous Article

What's The Most Forgettable Car?

Next Article

PepsiCo tees up functional innovation with Gatorade & Propel

Related Posts

Bain buys Mitsubishi pharma unit; Bausch + Lomb deal talks come up empty

Bain buys Mitsubishi pharma unit; Bausch + Lomb deal ta...

Feb 9, 2025  0

Lilly expands US manufacturing build-out with $50B target

Lilly expands US manufacturing build-out with $50B target

Feb 26, 2025  0

RFK Jr. confirmed by Senate as health secretary

RFK Jr. confirmed by Senate as health secretary

Feb 13, 2025  0